chronic kidney disease stage 3-4 with hyperkalaemia
Endocrinology · 2022–2023
2decisions
1medicine
2carried consumer input
1individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| patiromer Initial treatment of adult patients with chronic kidney disease (CKD) Stage 3-4, with chronic hyperkalaemia (at least two episodes of serum potassium 6.0… | Mar 2023 | Recommended | input received |
| patiromer Initial treatment of adult patients with chronic kidney disease (CKD) Stage 3-4, with chronic hyperkalaemia (at least 2 episodes of serum potassium 6.0 mmol/L… | Nov 2022 | Not recommended | 1 individuals |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.